Initial Results of a Positron Tomograph for Prostate Imaging

We present the status and initial images of a positron tomograph for prostate imaging that centers a patient between a pair of external curved detector banks (ellipse: 45 cm minor, 70 cm major axis). The distance between detector banks adjusts to allow patient access and to position the detectors as closely as possible for maximum sensitivity with patients of various sizes. Each bank is composed of two axial rows of 20 CTI PET Systems HR+ block detectors for a total of 80 detectors in the camera. Compared to an ECAT HR PET system operating in 3D mode, our camera uses about one-quarter the number of detectors and has approximately the same sensitivity for a central point source, because our detectors are close to the patient. The individual detectors are angled in the plane to point towards the prostate to reduce resolution degradation in that region. The detectors are read out by modified CTI data acquisition electronics. We have completed construction of the gantry and electronics, have developed detector calibration and data acquisition software, and are taking coincidence data. We demonstrate that we can clearly visualize a "prostate" in a simple phantom. Reconstructed images of two phantoms are shown

[1]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  J. Kurhanewicz,et al.  Improved prostate cancer imaging with SPECT/CT and MRI/MRSI , 2004, IEEE Transactions on Nuclear Science.

[3]  R. Coleman,et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  T. Shiga,et al.  Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Mithat Gonen,et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Coleman,et al.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. , 2001, Cancer research.

[7]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[8]  N. Shinoura,et al.  Brain tumors: detection with C-11 choline PET. , 1997, Radiology.

[9]  T. Turkington,et al.  PET prostate imaging with small planar detectors , 2004, IEEE Symposium Conference Record Nuclear Science 2004..

[10]  T. Hara,et al.  Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Ronald H. Huesman,et al.  Conceptual design of a compact positron tomograph for prostate imaging , 2000 .

[12]  W Vaalburg,et al.  Imaging of bladder cancer using C-11 choline positron emission tomography (PET). , 2000 .

[13]  J. Kurhanewicz,et al.  Improved prostate cancer imaging with SPECT/CT and MRI/MRSI , 2005, IEEE Symposium Conference Record Nuclear Science 2004..

[14]  Ludwig G Strauss,et al.  PET imaging of prostate cancer with 11C-acetate. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  N. Shinoura,et al.  PET imaging of brain tumor with [methyl-11C]choline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[17]  Nobuyuki Oyama,et al.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Z. Lengyel,et al.  Detection of prostate cancer with 11C-methionine positron emission tomography. , 2005, The Journal of urology.

[20]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[21]  W. W. Moses,et al.  List-mode maximum-likelihood reconstruction applied to positron emission mammography (PEM) with irregular sampling , 2000, IEEE Transactions on Medical Imaging.

[22]  J. Humm,et al.  Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[23]  S. Rosenthal,et al.  Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. , 1996, Clinical nuclear medicine.

[24]  G. Llosá First Results in the Development of a Compton Probe Prototype for Prostate Imaging , 2004 .

[25]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[26]  J. Karstens,et al.  Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[28]  N. Clinthorne,et al.  Performance evaluation of Compton probe and SPECT in lesion detection , 2004, IEEE Symposium Conference Record Nuclear Science 2004..

[29]  Magnus Dahlbom,et al.  Factor analysis in prostate cancer: delineation of organ structures and automatic generation of in- and output functions , 2002 .